Influenza viruses resistant to the antiviral drug oseltamivir: Transmission studies in ferrets

Journal of Infectious Diseases

Volumn 190, Issue 9, 2004, Pages 1627-1630

  Herlocher, M Louise ^a   Truscon, Rachel ^a   Elias, Stephanie ^a   Yen, Hui Ling ^a   Roberts, Noel A ^b   Ohmit, Suzanne E ^a   Monto, Arnold S ^a  

^a UNIVERSITY OF MICHIGAN   (United States)

^b ROCHE PRODUCTS LTD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

OSELTAMIVIR; SIALIDASE; SIALIDASE INHIBITOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBIOTIC RESISTANCE; ARTICLE; CONTROLLED STUDY; DRUG ISOLATION; EXPERIMENTAL MODEL; GENE MUTATION; GENOTYPE; INFLUENZA; INFLUENZA VIRUS; INFLUENZA VIRUS A; NONHUMAN; PRIORITY JOURNAL; VIRUS MUTANT; VIRUS TRANSMISSION; WILD TYPE;

ACETAMIDES; AMINO ACID SUBSTITUTION; ANIMALS; ANTIVIRAL AGENTS; DISEASE MODELS, ANIMAL; DRUG RESISTANCE, VIRAL; FERRETS; INFLUENZA A VIRUS; MUTATION; NEURAMINIDASE; ORTHOMYXOVIRIDAE INFECTIONS; OSELTAMIVIR; VIRAL PROTEINS;

EID: 6944227719     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/424572     Document Type: Article

References (15)

1. Gubareva LV, Kaiser L, Hayden FG. Influenza virus neuraminidase inhibitors. Lancet 2000; 355:827-35.
2. Hayden FG, Osterhaus ADME, Treanor JJ, et al. Efficacy and safety of the neuraminidase inhibitor zanamivir in the treatment of influenza virus infections. N Engl J Med 1997; 337:874-80.
3. Treanor JJ, Haydne FG, Vrooman PS, et al. Efficacy and safety of the oral neuraminidase inhibitor oseltamivir in treating acute influenza. JAMA 2000; 283:1016-24.
4. Zambon M, Hayden FG. Position statement: global Neuraminidase Inhibitor Susceptibility Network (NISN). Antiviral Res 2001; 49:147-56.
5. McKimm-Breschkin JL. Resistance of influenza viruses to neuraminidase inhibitors - a review. Antiviral Res 2000; 47:1-17.
6. Whitley RJ, Hayden FG, Reisinger KS, et al. Oral oseltamivir treatment of influenza in children. Pediatr Infect Dis J 2001; 20:127-33.
7. Carr J, Ives J, Kelly L, et al. Influenza virus carrying neuraminidase with reduced sensitivity to oseltamivir carboxylate has altered properties in vitro and is compromised for infectivity and replicative ability in vivo. Antiviral Res 2002; 54:79-88.
8. Ives JAL, Carr JA, Mendel DB, et al. The H274Y mutation in the influenza A/H1N1 neuraminidase active site following oseltamivir phosphate treatment leave virus severely compromised both in vitro and in vivo. Antiviral Res 2002; 55:307-17.
9. Colacino JM, Chirgadze NY, Garman E, et al. A single sequence change destabilizes the influenza virus neuraminidase tetramer. Virology 1997; 236:66-75.
10. Herlocher ML, Truscon R, Fenton R, et al. Assessment of development of resistance to antivirals in the ferret model of influenza virus infection. J Infect Dis 2003; 188:1355-61.
11. Herlocher ML, Elias S, Truscon R, et al. Ferrets as a transmission model for influenza: sequence changes in HA1 of type A (H3N2) virus. J Infect Dis 2001; 184:542-6.
12. Reuman PD, Keely S, Schiff GM, James N. Assessment of signs of influenza illness in the ferret model. J Virol Methods 1989; 24:27-34.
13. Herlocher ML, Carr J, Ives J, et al. Influenza virus carrying an R292K mutation in the neuraminidase gene is not transmitted in ferrets. Antiviral Res 2002; 54:99-111.
14. Jackson HC, Roberts N, Wange ZM, Belshe R. Management of influenza: use of new antivirals and resistance in perspective. Clin Drug Investig 2000; 20:447-54.
15. Hayden FG, Sperber SJ, Belshe RB, Clover RD, Hay AJ, Pyke S. Recovery of drug-resistant influenza A virus during therapeutic use of rimantadine. Antimicrob Agents Chemother 1991; 35:1741-7.